scholarly journals Comorbid physical illnesses in adult outpatients with psychotic disorders: risk factors, psychological functioning, and quality of life outcomes

Author(s):  
Wen Lin Teh ◽  
Laxman Cetty ◽  
Anitha Jeyagurunathan ◽  
Fiona Devi ◽  
Kumarasan Roystonn ◽  
...  

Abstract Purpose In contrast to global research, where physical comorbidity in psychotic disorders is established, only a few studies have been conducted in Southeast Asia. With a concerning trend of chronic physical illnesses emerging in adults below the age of 65, an investigation into comorbid chronic physical illnesses in adults diagnosed with psychotic disorders is necessary. This study aims to explore the risk factors, psychological functioning, and quality of life outcomes associated with comorbidity in adults below the age of 65, diagnosed with psychotic disorders, in a multi-ethnic non-Western setting. Methods Electronic medical records of 364 patients with psychotic disorders who had provided written consent to participate were screened for co-occurring physical conditions. The majority of participants were female (53.7%), Chinese (69%), single (74.5%), and had tertiary and above education (43%). They were approximately 35 years old on average and the mean age of onset for psychosis was 26.7 years old. Results Comorbid physical illnesses were present in approximately a third of adults with psychotic disorders (28%). They typically reported cardiovascular-related diseases, respiratory, and skin conditions. Comorbidity was significantly related to lower physical quality of life. As compared to other types of psychotic disorders, schizophrenia was significantly related to a greater frequency of comorbid physical conditions. Multinomial regression analyses revealed that age, age of onset, Malay and Indian ethnicities were significant factors. Conclusion Physical comorbidity in adults below the age of 65 is common, signifying an emerging need to place greater attention into the screening and emphasis on the physical care needs of this age group. Finally, more research is needed to understand the impact of common co-occurring acute and chronic cardiovascular, skin, and respiratory diseases locally.

Spine ◽  
2017 ◽  
Vol 42 (19) ◽  
pp. 1502-1510 ◽  
Author(s):  
Takahiro Makino ◽  
Takashi Kaito ◽  
Hiroyasu Fujiwara ◽  
Hirotsugu Honda ◽  
Yusuke Sakai ◽  
...  

2001 ◽  
Vol 166 (5) ◽  
pp. 1804-1810 ◽  
Author(s):  
CONSTANCE G. BACON ◽  
EDWARD GIOVANNUCCI ◽  
MARCIA TESTA ◽  
ICHIRO KAWACHI

2015 ◽  
Vol 6 (4) ◽  
pp. 306-313 ◽  
Author(s):  
Matthew D. Alvin ◽  
Jacob A. Miller ◽  
Daniel Lubelski ◽  
Amy S. Nowacki ◽  
Judith Scheman ◽  
...  

2015 ◽  
Vol 15 (1) ◽  
pp. 79-85 ◽  
Author(s):  
Matthew D. Alvin ◽  
Jacob A. Miller ◽  
Swetha Sundar ◽  
Megan Lockwood ◽  
Daniel Lubelski ◽  
...  

2016 ◽  
Vol 16 (6) ◽  
pp. 714-721 ◽  
Author(s):  
Michael P. Silverstein ◽  
Jacob A. Miller ◽  
Roy Xiao ◽  
Daniel Lubelski ◽  
Edward C. Benzel ◽  
...  

2020 ◽  
Author(s):  
Zoé Tremblay ◽  
David Mumbere-Bamusemba ◽  
Danielle Laurin ◽  
Caroline Sirois ◽  
Daniela Furrer ◽  
...  

BACKGROUND Deprescribing, a relatively recent concept, has been proposed as a promising solution to the growing issues of polypharmacy and use of medications of questionable benefit among older adults. However, little is known about the health outcomes of deprescribing interventions. OBJECTIVE This study aims to contribute to the knowledge on deprescribing by addressing two specific objectives: 1) describe the impact of deprescribing in adults’ ≥60 years on health outcomes or quality of life; and 2) determine the characteristics of effective interventions in deprescribing. METHODS Primary studies targeting three concepts (older adults, deprescribing, and health/quality of life outcomes) will be included in the review. The search will be performed using key international databases (MEDLINE, EMBASE, CINAHL, Ageline, PsycInfo) and a special effort will be made to identify grey literature. Two reviewers will independently screen the articles, extract the information and evaluate the quality of the selected studies. If methodologically feasible, meta-analyses will be performed for groups of intervention studies reporting on deprescribing interventions for similar medications, used for similar or identical indications and reporting on similar outcomes (for example benzodiazepines used against insomnia and reporting on quality of sleep or quality of life). Alternatively, results will be presented in bottom-line statements (Objectives 1) and a matrix outlining effective interventions (Objective 2). RESULTS The knowledge synthesis may be limited by the availability of high-quality, clinical trials on deprescribing and its outcomes in older adults. Additionally, analyses will likely be affected by studies on the deprescribing of different types of molecules within the same indication, e.g. different pharmacological classes and medications to treat hypertension, and different measures of health and quality of life outcomes for the same indication. CONCLUSIONS Deprescribing becomes more widespread, therefore knowledge on its effects on health are needed. CLINICALTRIAL CRD42015020866


Sign in / Sign up

Export Citation Format

Share Document